Alnylam Pharmaceuticals, Inc. News Releases http://investors.alnylam.com/ Alnylam Pharmaceuticals, Inc. News Releases en Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-6 − Achieved Fourth Quarter 2018 ONPATTRO® Global Net Product Revenues of $12.1 Million , with Over 200 Patients on Commercial Product in U.S. and EU as of Year-End 2018 – − Obtained Regulatory Alignment on APOLLO-B Phase 3 Study of Patisiran in ATTR Amyloidosis with Cardiomyopathy and Initiated Thu, 07 Feb 2019 16:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23496 Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-publication-phase-1-givosiran-data-new-england − Givosiran Associated with Substantial and Sustained Lowering of Neurotoxic Heme Synthesis Intermediates Implicated in Acute Intermittent Porphyria – − Givosiran also Associated with Reduced Rate of Porphyria Attacks and Hemin Use – − Topline Phase 3 Readout Expected in Early 2019, with a Rolling Wed, 06 Feb 2019 17:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23476 Alnylam to Webcast Presentations at Upcoming February Investor Conferences http://investors.alnylam.com/news-releases/news-release-details/alnylam-webcast-presentations-upcoming-february-investor-1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, Mon, 04 Feb 2019 16:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23466 Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results http://investors.alnylam.com/news-releases/news-release-details/alnylam-webcast-conference-call-discussing-fourth-quarter-and-10 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019 , after the U.S. Thu, 31 Jan 2019 16:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23446 Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-and-medison-pharma-partner-commercialize ZUG, Switzerland & PETACH TIKVA, Israel --(BUSINESS WIRE)--Jan. 21, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to Mon, 21 Jan 2019 03:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23421 Alnylam Pharmaceuticals Prices Public Offering of Common Stock http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-prices-public-offering-common-stock-4 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 14, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. Mon, 14 Jan 2019 21:13:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23401 Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-announces-proposed-public-offering-2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 14, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter a Mon, 14 Jan 2019 16:04:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23391 Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-unaudited-fourth-quarter-2018-global-revenues − Achieved Fourth Quarter 2018 ONPATTRO Unaudited Global Net Product Revenues of $11-12 Million – − Over 200 Patients on Commercial ONPATTRO in U.S. and EU from Launch Through Year-End 2018 – − Maintained Strong Balance Sheet with Unaudited Year-End Cash and Investments Balance of Approximately Mon, 07 Jan 2019 08:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23371 Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference http://investors.alnylam.com/news-releases/news-release-details/alnylam-webcast-presentation-37th-annual-jp-morgan-healthcare CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 28, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT ( Fri, 28 Dec 2018 07:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23356 Alnylam Announces Settlement of Litigation with Silence Therapeutics http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-settlement-litigation-silence-therapeutics CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 10, 2018-- Alnylam Pharmaceuticals, Inc.  (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics . The settlement allows Alnylam to avoid the costs and distraction Mon, 10 Dec 2018 02:00:00 -0500 Alnylam Pharmaceuticals, Inc. News Releases 23341